Lever Bio

A differentiated approach designed to reprogramme the tumour microenvironment and expand the potential of cancer immunotherapy.

Lever Bio is developing next-generation cancer immunotherapies designed to reprogramme the solid tumour microenvironment and enhance anti-cancer immune responses.

Its pipeline encompasses multiple immuno-oncology assets targeting metabolic and structural barriers within the tumour microenvironment. Through mechanisms including tumour vasculature normalisation, modulation of immunosuppressive stromal cells, and metabolic potentiation of cytotoxic T cells, Lever Bio’s compounds are engineered to restore T-cell fitness, prevent exhaustion, and overcome resistance to current immunotherapies.

Lever Bio collaborates with leading academic and research institutions to advance its portfolio of tumour-microenvironment reprogrammers and T-cell-fitness potentiators through discovery and preclinical stages, with the goal of delivering biomarker-driven combination therapies for hard-to-treat solid tumours.